Xsulin 30/70 Eris1pen Injection contains human insulin at a concentration of 100 IU/ml, formulated as a premixed suspension comprising 30% soluble insulin and 70% isophane insulin. This combination provides both rapid onset and prolonged duration of action, facilitating effective glycemic control in patients with diabetes mellitus. The soluble insulin component initiates glucose uptake shortly after administration, while the isophane insulin ensures sustained insulin activity, reducing the frequency of injections required. Xsulin 30/70 is indicated for the management of type 1 and type 2 diabetes when diet, exercise, and oral hypoglycemic agents alone are insufficient to achieve adequate glycemic control. It is administered subcutaneously, typically before meals, with dosage individualized based on blood glucose monitoring and patient response. Proper injection technique and rotation of injection sites are essential to minimize local adverse effects such as lipodystrophy. Patients should be educated on recognizing and managing hypoglycemia, a potential risk associated with insulin therapy. This product should be stored under recommended conditions to maintain potency. Xsulin 30/70 Eris1pen offers a convenient and effective option for insulin therapy, combining immediate and intermediate action to optimize blood glucose regulation.